Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Urology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
ARV-110-mCRPC-103ARV-110 and Abiraterone in Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC): A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone in Patients with Metastatic Prostate Cancer | |
|---|---|
| Local Project Reference: | 146192 |
| Principal Investigator: | Dr. Mark Linch |
| Drug Class/ Treatment: | ARV-110 (Androgen Receptor Proteolysis Targeting Chimera Protein Degrader) + Abiraterone |
| Patient Population: | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
POTENTIA (CBT307-1)A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours (POTENTIA) | |
|---|---|
| Local Project Reference: | 129679 |
| Principal Investigator: | Dr. Anuradha Jayaram |
| Drug Class/ Treatment: | CB307 (Trispecific Humabody T-Cell Enhancer) |
| Patient Population: | PSMA+ (IHC) Advanced or Metastatic Solid Tumours |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
BAYER 20511Radium-223 biodistribution study in patients with bone metastatic CRPC: Open-label, non-randomized Phase 1, multicenter study to assess radium-223 biodistribution in participants with bone metastatic castration resistant prostate cancer (CRPC) receiving radium-223 dichloride treatment. | |
|---|---|
| Local Project Reference: | 129692 |
| Principal Investigator: | Dr. Ursula McGovern |
| Drug Class/ Treatment: | Radium-223 Dichloride (α-emitter Radionuclide) |
| Patient Population: | Bone Metastatic Castration Resistant Prostate Cancer (CRPC) |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
DURANCEDURANCE: A phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr | |
|---|---|
| Local Project Reference: | 121881 |
| Principal Investigator: | Dr. Mark Linch |
| Drug Class/ Treatment: | Durvalumab (PD-L1 Blocking IgG1 Kappa Monoclonal Antibody) + S-488210/S-488211 (Peptide Vaccine) |
| Patient Population: | Non-Muscle Invasive Bladder Cancer |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
ABACUS-2ABACUS-2: Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer | |
|---|---|
| Local Project Reference: | 135538 |
| Principal Investigator: | Dr. Mark Linch |
| Drug Class/ Treatment: | Atezolizumab (IgG1 Isotype Monoclonal Antibody against PD-L1) |
| Patient Population: | Non-Muscle Invasive Bladder Cancer |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
EPICEPIC Trial: A Phase II Trial of Cemiplimab alone or in combination with Standard of Care Chemotherapy in Locally Advanced or Metastatic Penile Carcinoma | |
|---|---|
| Local Project Reference: | 126549 |
| Principal Investigator: | Dr. Constantine Alifrangis |
| Drug Class/ Treatment: | Cemiplimab (Humanised Monoclonal IgG4 Antibody Targeting PD-1/PD-L1 Pathway) Monotherapy or Combination with SOC Chemotherapy |
| Patient Population: | Non-Muscle Invasive Bladder Cancer |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
BXCL701-201A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with mCRPC either Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC) or Adenocarcinoma Phenotype | |
|---|---|
| Local Project Reference: | 113103 |
| Principal Investigator: | Dr Mark Linch |
| Drug Class/ Treatment: | BXCL701 (Dipeptidyl Peptidases Inhibitor) + Pembrolizumab (PD-1 Monoclonal Antibody) |
| Patient Population: | Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC) |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
PRO-MERIT(Prostate Cancer Messenger RNA Immunotherapy): A first-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W_pro1 in patients with metastatic castration resistant prostate cancer and W_pro1 in combination with cemiplimab and/or goserelin acetate in patients with high-risk, localized prostate cancer. | |
|---|---|
| Local Project Reference: | 122815 |
| Principal Investigator: | Dr Mark Linch |
| Drug Class/ Treatment: | W_pro1 (mRNA Cancer Vaccine) |
| Patient Population: | Group 1: mCRPC that have exhausted conventional treatment |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
